Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Creative Commons License

Yekeduz E., ÖZBAY M. F., Caglayan D., YILDIRIM A., Erol C., YILDIRIM H. Ç., ...Daha Fazla

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.78, sa.12, ss.1973-1979, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 78 Sayı: 12
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s00228-022-03403-1
  • Dergi Adı: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, Chimica, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1973-1979
  • Anahtar Kelimeler: Drug-drug interactions, Acid suppression, Regorafenib, TYROSINE-KINASE INHIBITORS, DRUG-DRUG INTERACTIONS, SOLID TUMORS, TRANSPORTERS, RESISTANCE, THERAPY
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Aim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib.